T-CURX

T-CURX GmbH is a private biopharmaceutical company focused on the development and commercialization of next-generation CAR-T cell therapies for cancer indications with high medical needs. The company's proprietary CAR-T technology, headquartered in Germany, was developed in the laboratory of co-founder Professor Michael Hudecek at the University of Würzburg. At its core is a novel Sleeping Beauty ("SB") transposon gene transfer technology, exclusively licensed to T-CURX.T-CURX leverages several cutting-edge CAR-T engineering technologies, including virus-free transposon-based genetic engineering and a highly flexible modular CAR format.